Leerink Partnrs Raises Earnings Estimates for AbbVie

AbbVie Inc. (NYSE:ABBV) – Equities research analysts at Leerink Partnrs increased their FY2026 EPS estimates for AbbVie in a note issued to investors on Monday, April 21st. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings per share of $13.99 for the year, up from their previous estimate of $13.97. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share. Leerink Partnrs also issued estimates for AbbVie’s FY2027 earnings at $15.69 EPS, FY2028 earnings at $17.51 EPS and FY2029 earnings at $18.85 EPS.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same quarter in the prior year, the firm earned $2.79 earnings per share.

Several other analysts have also recently commented on ABBV. Citigroup increased their target price on AbbVie from $205.00 to $215.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Cantor Fitzgerald started coverage on shares of AbbVie in a research report on Tuesday. They issued an “overweight” rating and a $210.00 price objective for the company. StockNews.com lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, April 9th. Guggenheim reissued a “buy” rating and set a $214.00 price target on shares of AbbVie in a research note on Thursday, April 17th. Finally, UBS Group boosted their price objective on shares of AbbVie from $181.00 to $190.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Seven research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $211.19.

AbbVie Stock Up 2.0 %

Shares of ABBV opened at $177.28 on Wednesday. The business’s 50 day simple moving average is $197.30 and its 200-day simple moving average is $187.37. AbbVie has a one year low of $153.58 and a one year high of $218.66. The company has a market capitalization of $313.60 billion, a P/E ratio of 73.87, a PEG ratio of 1.62 and a beta of 0.55. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be paid a $1.64 dividend. This represents a $6.56 annualized dividend and a dividend yield of 3.70%. The ex-dividend date of this dividend is Tuesday, April 15th. AbbVie’s dividend payout ratio is 273.33%.

Insider Transactions at AbbVie

In related news, EVP Perry C. Siatis sold 5,778 shares of AbbVie stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $197.90, for a total value of $1,143,466.20. Following the sale, the executive vice president now owns 22,381 shares of the company’s stock, valued at approximately $4,429,199.90. The trade was a 20.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Kevin K. Buckbee sold 18,944 shares of the stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $203.41, for a total value of $3,853,399.04. Following the transaction, the senior vice president now directly owns 11,496 shares of the company’s stock, valued at $2,338,401.36. This trade represents a 62.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 113,471 shares of company stock valued at $23,426,451 over the last three months. Company insiders own 0.25% of the company’s stock.

Institutional Investors Weigh In On AbbVie

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Norges Bank acquired a new stake in AbbVie in the fourth quarter valued at $4,459,385,000. GAMMA Investing LLC grew its holdings in AbbVie by 25,841.6% during the first quarter. GAMMA Investing LLC now owns 10,234,737 shares of the company’s stock worth $2,144,382,000 after purchasing an additional 10,195,284 shares during the period. Raymond James Financial Inc. acquired a new position in AbbVie during the fourth quarter worth approximately $1,190,951,000. FMR LLC raised its stake in AbbVie by 32.8% in the fourth quarter. FMR LLC now owns 18,097,375 shares of the company’s stock valued at $3,215,903,000 after buying an additional 4,466,971 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of AbbVie by 15.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 27,436,133 shares of the company’s stock valued at $4,875,401,000 after buying an additional 3,599,336 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.